Spots Global Cancer Trial Database for thalassemia
Every month we try and update this database with for thalassemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Massive Iron Deposit Assessment | NCT01572922 | Iron Overload Excessive Body ... | R2*-UTE R2*-GRE Liver biopsy | - | St. Jude Children's Research Hospital | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation | NCT01316549 | Hematologic Mal... Nonmalignant Di... Immunodeficienc... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Fludarabine | - 17 Years | University of California, San Francisco | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Massive Iron Deposit Assessment | NCT01572922 | Iron Overload Excessive Body ... | R2*-UTE R2*-GRE Liver biopsy | - | St. Jude Children's Research Hospital | |
| Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients | NCT05255445 | Sickle Cell Dis... Thalassemia Pediatric Cance... | Red Blood Cell ... | - | Westat | |
| This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. | NCT01250951 | Myelodysplastic... Thalassemia | Deferasirox | 2 Years - | Novartis | |
| Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | NCT03609840 | Hematologic Mal... Nonmalignant Di... Immune Deficien... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Thiotepa | - 17 Years | University of California, San Francisco | |
| Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | NCT03609840 | Hematologic Mal... Nonmalignant Di... Immune Deficien... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Thiotepa | - 17 Years | University of California, San Francisco | |
| Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation | NCT01316549 | Hematologic Mal... Nonmalignant Di... Immunodeficienc... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Fludarabine | - 17 Years | University of California, San Francisco | |
| Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations | NCT01911871 | Thalassemia Sickle Cell Dis... Myelodysplasia | Blood sample | 6 Years - | Assistance Publique - Hôpitaux de Paris | |
| CINC424A2X01B Rollover Protocol | NCT02386800 | Primary Myelofi... Polycythemia Ve... Graft Versus Ho... Acute Myeloid L... Thalassemia | ruxolitinib panobinostat | 1 Month - | Novartis | |
| Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | NCT03609827 | Hematologic Mal... Nonmalignant Di... Immunodeficienc... Hemoglobinopath... Genetic Inborn ... Fanconi's Anemi... Thalassemia Sickle Cell Dis... | Melphalan | - 17 Years | University of California, San Francisco | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants | NCT01881334 | Hematologic Mal... Inborn Errors o... Immune Deficien... | CliniMACS CD34 ... | - 65 Years | Duke University | |
| A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | NCT05736419 | Sickle Cell Dis... Thalassemia, Be... Thalassemia | Fludarabine Cyclophosphamid... Tacrolimus Mycophenolate M... Rabbit ATG Dexamethasone Bortezomib Rituximab | 2 Years - 50 Years | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
